Advertisement
State of Art| Volume 35, ISSUE 6, P695-703, June 2016

Download started.

Ok

Update in treatment options in pulmonary hypertension

Published:January 15, 2016DOI:https://doi.org/10.1016/j.healun.2016.01.020
      Significant developments have occurred in the field of pulmonary hypertension (PH) in the past 2 years, especially in terms of treatment options available. These include: approval of new drugs; evidence for use of initial combination therapies in pulmonary arterial hypertension; approved drugs for use in chronic thromboembolic disease not amenable to, or persistent after surgical thromboendarterectomy; and ongoing clinical trials in PH related to left heart disease and hypoxia. The field continues to evolve and address the challenges in treatment of this multifaceted disease with the aim to provide novel solutions and meet the needs of a growing population with PH. This has led to an extensive body of literature, ranging from case series to prospective, multicenter clinical trials, which will enhance the future of patient outcomes in PH. This contemporary review highlights the key articles in treatment updates for PH for the years 2013 to 2015.

      Keywords

      Pulmonary hypertension (PH) is a complex disorder involving multiple clinical conditions, including intrinsic pulmonary vascular disease, left heart disease and lung disorders, causing hypoxia, which is usually associated with a poor prognosis.
      • McLaughlin V.V.
      • Archer S.L.
      • Badesch D.B.
      • et al.
      ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association.
      During the Fifth World Symposium held in 2013, several modifications were made to the previous clinical classification, especially in the nomenclature of the Group I sub-category of pulmonary arterial hypertension (PAH).
      • Simonneau G.
      • Gatzoulis M.A.
      • Adatia I.
      • et al.
      Updated clinical classification of pulmonary hypertension.
      There has been a recent surge in available therapeutic options as well as investigational trials for the treatment of PH, with 3 drugs (macitentan, riociguat and treprostinil diolamine) being approved for PAH in the last 18 months.
      • Galie N.
      • Corris P.A.
      • Frost A.
      • et al.
      Updated treatment algorithm of pulmonary arterial hypertension.
      However, all trials using PAH-approved therapies have failed to demonstrate a benefit in the context of heart failure, which is the most common etiology of PH. In this article, we review the literature from last 2 years and provide an update on the management of PH.

      Updates in PAH: World Health Organization Group I

      PAH is characterized by pulmonary vascular remodeling leading to right ventricular failure and, without treatment, ultimately death.
      • Farber H.W.
      • Loscalzo J.
      Pulmonary arterial hypertension.
      Although survival in PAH has improved significantly in the current era, it continues to remain high with a 1-year mortality of ~15%.
      • Thenappan T.
      • Shah S.J.
      • Rich S.
      • et al.
      Survival in pulmonary arterial hypertension: a reappraisal of the NIH risk stratification equation.
      • Benza R.L.
      • Miller D.P.
      • Gomberg-Maitland M.
      • et al.
      Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL).
      The treatment options for PAH patients have evolved progressively in the past few years, increasing in complexity and in evidence for efficacy.
      • Galiè N.
      • Humbert M.
      • Vachiery J.L.
      • et al.
      2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: the Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS) Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT).
      Currently approved therapies for PAH target the 3 main pathways implicated in the pathogenesis of pulmonary vascular remodeling: prostacyclin (epoprostenol, treprostinil and iloprost); endothelin (bosentan, ambrisentan and macitentan); the nitric oxide pathway (sildenafil, tadalafil and riociguat) (Figure 1).
      • Galie N.
      • Corris P.A.
      • Frost A.
      • et al.
      Updated treatment algorithm of pulmonary arterial hypertension.
      • Tuder R.M.
      • Archer S.L.
      • Dorfmuller P.
      • et al.
      Relevant issues in the pathology and pathobiology of pulmonary hypertension.
      Although some of these drugs have resulted in delay in clinical worsening noted in PAH patients, their impact on reducing premature death due to PAH continues to be limited.
      Figure thumbnail gr1
      Figure 1The 3 major pathogenetic pathways targeted by current therapies in pulmonary arterial hypertension. Reproduced with permission from Humbert et al.
      • Humbert M.
      • Lau E.M.
      • Montani D.
      • et al.
      Advances in therapeutic interventions for patients with pulmonary arterial hypertension.

      Prostacyclin pathway

      Oral treprostinil

      Treprostinil diolamine is an oral, salt form of treprostinil that was recently approved as monotherapy in PAH patients, based on findings from the FREEDOM M trial.
      • Jing Z.C.
      • Parikh K.
      • Pulido T.
      • et al.
      Efficacy and safety of oral treprostinil monotherapy for the treatment of pulmonary arterial hypertension: a randomized, controlled trial.
      During this randomized, placebo-controlled, Phase III study, oral treprostinil improved 6-minute walk distance (6MWD) by 23 meters at 12 weeks in 349 treatment-naive PAH patients (95% confidence interval 4 to 41 m, p = 0.0125). However, there was no improvement in functional class or time to clinical worsening.
      • Jing Z.C.
      • Parikh K.
      • Pulido T.
      • et al.
      Efficacy and safety of oral treprostinil monotherapy for the treatment of pulmonary arterial hypertension: a randomized, controlled trial.
      The common side effects of oral treprostinil in the clinical trials were nausea, diarrhea, headache and jaw pain. It is better tolerated when started at a lower, divided dose (usually 0.125 mg or 0.25 mg) and increased very gradually every 3 or 4 days. Because it is metabolized predominantly in the liver by CP2YC8 enzyme, it is contraindicated in patients with severe hepatic impairment (Child–Pugh Stage 3).
      • Peterson L.
      • Marbury T.
      • Marier J.
      • et al.
      An evaluation of the pharmacokinetics of treprostinil diolamine in subjects with hepatic impairment.
      Although not contraindicated in pregnancy, its use in pregnancy has been discouraged (Category C).

      Selexipag

      Selexipag is an orally available, non-prostanoid, highly selective agonist of inositol triphosphate (IP) receptor.
      • Morrison K.
      • Ernst R.
      • Hess P.
      • et al.
      Selexipag: a selective prostacyclin receptor agonist that does not affect rat gastric function.
      Both the parent drug and its metabolite have a high affinity for the IP receptor compared with other protanoid receptors. This selectivity allows for minimal side effects (nausea, vomiting, diarrhea and jaw pain), better tolerability and successful dose escalation. In a Phase II, placebo-controlled trial, selexipag decreased pulmonary vascular resistance (PVR) by 30% after 17 weeks of treatment in PAH patients stable on background therapy.
      • Simonneau G.
      • Torbicki A.
      • Hoeper M.M.
      • et al.
      Selexipag: an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension.
      It was well tolerated with no death or unexpected serious adverse events in this trial. Subsequently, the long-term effect of selexipag was evaluated in the recently completed, event-driven GRIPHON trial, which was a multicenter, double-blind, placebo-controlled trial of 1,156 patients who were randomized in a 1:1 fashion to selexipag or placebo.
      • Sitbon O
      • Channick R
      • Chin K
      • et al.
      Selexipag for the Treatment of Pulmonary Arterial Hypertension.
      The primary end-point was a composite of death, lung transplantation, atrial septostomy, hospitalization for worsening PAH or worsening PAH. Selexipag was started at 200 μg twice daily and gradually up-titrated to a maximum of 1,600 μg twice daily, as tolerated. It was well tolerated and prostacyclin side effects were less frequent (>3% vs placebo). It reduced the risk of primary end-point by 40% compared with placebo (hazard ratio [HR] = 0.60; 99% confidence interval [CI] 0.46 to 0.78; p < 0.0001). The drug is currently under review by the United States Food and Drug Administration (FDA) and the European Medical Agency (EMA).

      Endothelin pathway

      Macitentan

      Macitentan is an oral, non-selective dual-endothelin receptor (A and B) antagonist recently approved for the treatment of PAH. The drug was evaluated in a long-term randomized, double-blind, placebo-controlled, multicenter trial (SERAPHIN).
      • Pulido T.
      • Adzerikho I.
      • Channick R.N.
      • et al.
      Macitentan and morbidity and mortality in pulmonary arterial hypertension.
      This was the first event-driven trial assessing long-term morbidity and mortality as the primary end-point in PAH. In this trial, 750 patients were randomized in a 1:1:1 fashion to placebo, macitentan 3 mg/day and macitentan 10 mg/day, respectively. The primary end-point was similar to the GRIPHON study and the median treatment duration was 32 months. Macitentan 3 mg/day and 10 mg/day reduced the risk of primary end-point, primarily driven by reduction in PAH worsening, by 30% (HR = 0.70; 97.5% CI 0.52 to 0.96; p = 0.01) and 45% (HR = 0.55; 97.5% CI 0.39 to 0.76; p < 0.001), respectively. There was no difference in all-cause mortality or mortality related to PAH between the treatment groups. The common side effects were headache, nasopharyngitis and anemia. With a more sustained receptor blockade and tissue penetration when compared with bosentan, its advantages include once-daily dosing, less drug–drug interaction (sildenafil and cyclosporine), and absence of association with increased incidence of liver function test abnormalities and edema.

      Nitric oxide pathway

      Riociguat

      Riociguat stimulates the nitric oxide (NO)-soluble guanylate cyclase (sGC)-cyclic guanosine monophosphate (cGMP) pathway independent of endogenous NO, leading to increased levels of cGMP and vasodilation.
      • Archer S.L.
      Riociguat for pulmonary hypertension—a glass half full.
      The safety and efficacy of riociguat in PAH was assessed in the PATENT-1 trial, an international, multicenter, randomized, placebo-controlled clinical trial.
      • Ghofrani H.A.
      • Galie N.
      • Grimminger F.
      • et al.
      Riociguat for the treatment of pulmonary arterial hypertension.
      A total of 443 patients with PAH, both treatment-naive and on background therapy, were randomized to either placebo, riociguat titrated to 1.5 mg 3 times daily or riociguat titrated to 2.5 mg 3 times daily. The latter dose increased 6MWD by 36 meters at 12 weeks (95% CI 20 to 52 weeks; p < 0.001). There were also improvements in PVR, N-terminal pro–brain natriuretic peptide (NT-pro-BNP), functional class and time to clinical worsening at 12 weeks compared with placebo. The beneficial effects were consistent, regardless of underlying functional class and background PAH therapy. The improvement in 6MWD was sustained at 24 weeks in the long-term extension study (PATENT 2).
      • Ghofrani H.A.
      • Galie N.
      • Grimminger F.
      • et al.
      Riociguat for the treatment of pulmonary arterial hypertension.
      Riociguat is teratogenic and therefore contraindicated in pregnancy. Finally, it should not be used together with a phosphodiesterase type 5 (PDE5) inhibitor due to increased incidence of hypotension. The combination of riociguat and sildenafil led to discontinuation of the drug and death in the blinded, randomized extension study in PAH patients (PATENT-PLUS).
      • Galie N.
      • Muller K.
      • Scalise A.V.
      • et al.
      PATENT PLUS: a blinded, randomised and extension study of riociguat plus sildenafil in pulmonary arterial hypertension.

      Sequential combination therapy

      When patients have an inadequate clinical response or deterioration in clinical status with monotherapy, a second agent targeting a different pathway is added. Although evidence for improvement in long-term clinical outcomes with sequential combination therapy in PAH is limited, current guidelines endorse this approach with a Level IA recommendation.
      • Galie N.
      • Corris P.A.
      • Frost A.
      • et al.
      Updated treatment algorithm of pulmonary arterial hypertension.
      Table 1 summarizes the clinical trials that have evaluated the efficacy and safety of sequential combination therapy in PAH.
      Table 1Clinical Trials of Combination Therapy in Pulmonary Arterial Hypertension
      Add on therapyBackground therapyPatients (n)StudyDurationPrimary end-pointComments
      NO pathway
       Riociguat
      • Archer S.L.
      Riociguat for pulmonary hypertension—a glass half full.
      (PATENT)
      ERA or prostanoidsIPAH, FPAH, CTD, CHD, portopulmonary and anorexigen PAH (ERA, n = 194; prostanoids, n = 28)Randomized, double-blind, placebo- controlled12 weeks6MWDPlacebo-adjusted increase of 36 m
      Endothelin pathway
       Bosentan
      • Galie N.
      • Muller K.
      • Scalise A.V.
      • et al.
      PATENT PLUS: a blinded, randomised and extension study of riociguat plus sildenafil in pulmonary arterial hypertension.
      (COMPASS-2)
      SildenafilIPAH, FPAH, CTD, CHD, and anorexigen PAH (n = 334)Randomized, double-blind, placebo-controlledEvent-driven trial; mean treatment duration 38.0 ± 21.9 monthsMorbidity/mortalityNo significant effect on morbidity/mortality
       Macitentan
      • Sitbon O
      • Channick R
      • Chin K
      • et al.
      Selexipag for the Treatment of Pulmonary Arterial Hypertension.
      (SERAPHIN)
      Sildenafil, tadalafil, or inhaled prostanoidIPAH, FPAH, CTD, CHD, HIV and anorexigen PAH (PDE5-I, n = 454; inhaled prostanoid, n = 40)Randomized, double-blind, placebo-controlledEvent-driven trial; median duration of treatment: 104 weeksMorbidity/mortality38% relative reduction compared with placebo
      Prostacyclin pathway
       Oral treprostinil
      • McLaughlin V.
      • Channick R.N.
      • Ghofrani H.A.
      • et al.
      Bosentan added to sildenafil therapy in patients with pulmonary arterial hypertension.
      (FREEDOM-C)
      PDE5-I and/or ERAIPAH, FPAH, CTD, CHD, HIV and anorexigen PAH (sildenafil, n = 88; bosentan, n = 106; bosentan + sildenafil, n = 156)Randomized, double-blind, placebo-controlled16 weeks6 MWDNo significant change
       Oral treprostinil
      • Tapson V.F.
      • Torres F.
      • Kermeen F.
      • et al.
      Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trial.
      (FREEDOM-C2)
      PDE5-I and/or ERAIPAH, FPAH, CTD, CHD, and HIV (PDE-5I, n = 132; ERA, n = 53; PDE-5I + ERA, n = 125)Randomized, double-blind, placebo-controlled16 weeks6 MWDNo significant change
      Initial combination therapy
       Ambrisentan and tadalafil vs ambrisentan vs tadalafil (2:1:1)NoneIPAH, FPAH, CTD, CHD, drugs, toxins and HIV, n = 500 (combination therapy, n = 253; ambrisentan, n = 126; tadalafil, n = 121)Randomized, double-blind, placebo-controlledEvent-driven trial, 6 monthsTime to clinical worseningInitial combination therapy with 50% RR reduction compared with pooled monotherapy
       AMBITION
      CHD, congenital heart disease; CTD, connective tissue disease; ERA, endothelin-receptor antagonist; FPAH, familial pulmonary arterial hypertension; HIV, human immunodeficiency virus; IPAN, idiopathic pulmonary arterial hypertension; NO, nitric oxide; PAH, pulmonary arterial hypertension; PDE5-I, phosphodiesterase-5 inhibitor; 6MWD, 6-minute walk distance.
      Of the total 742 patients in the SERAPHIN trial, 61% were on PDE5 inhibitor (PDE5-I) therapy and 6% were on oral or inhaled prostacyclin background therapy.
      • Sitbon O
      • Channick R
      • Chin K
      • et al.
      Selexipag for the Treatment of Pulmonary Arterial Hypertension.
      Compared with placebo, macitentan 10 mg/day delayed the time to composite clinical end-point in the subgroup of patients on background medical therapy (HR = 0.62; 95% CI 0.43 to 0.89; p = 0.009), but there was no difference between macitentan 3 mg/day and placebo (HR = 0.83; 95% CI 0.34 to 0.85; p = 0.27). In addition, in the subgroup of patients on background therapy, macitentan 10 mg increased 6MWD by at 6 months (vs placebo, 26 meters; 95% CI 4.5 to 47.3; p = 0.007) and there was a trend toward improvement in 6MWD with the macitentan 3-mg dose (vs placebo, +17.9 meters; 95% CI –5.0 to 40.8; p = 0.08). In the GRIPHON trial, selexipag delayed time to composite end-point of mortality and mortality, even in patients who were on background PAH therapies.
      • Sitbon O
      • Channick R
      • Chin K
      • et al.
      Selexipag for the Treatment of Pulmonary Arterial Hypertension.
      COMPASS 2 is the first event-driven clinical trial to study the effect of sequential combination therapy in PAH.
      • McLaughlin V.
      • Channick R.N.
      • Ghofrani H.A.
      • et al.
      Bosentan added to sildenafil therapy in patients with pulmonary arterial hypertension.
      In this randomized, double-blind, placebo-controlled clinical trial, 334 patients with PAH who were symptomatic on sildenafil for >3 months were randomized in a 1:1 fashion to either bosentan or placebo. In contrast to the subgroup analysis from the SERAPHIN trial, sequential combination therapy with sildenafil and bosentan was not superior to sildenafil monotherapy in delaying the time to first event of all-cause mortality; hospitalization for worsening PAH; or intravenous prostanoids initiation, atrial septostomy or transplant (HR = 0.83; 95% CI 0.58 to 1.19; p = 0.2508). However, on exploratory secondary analysis, bosentan and sildenafil combination therapy improved 6MWD at 16 weeks. A greater number of patients in the sildenafil and bosentan combination group had an adverse event leading to premature discontinuation from the study (24.5% vs 12.6% with sildenafil monotherapy) and also had significant liver function tests abnormalities (21.8% vs 6.4% with sildenafil monotherapy).
      • McLaughlin V.
      • Channick R.N.
      • Ghofrani H.A.
      • et al.
      Bosentan added to sildenafil therapy in patients with pulmonary arterial hypertension.
      In the FREEDOM C trial, oral treprostinil did not improve 6MWD at 16 weeks when added to background therapy with an endothelin-receptor antagonist (ERA) or PDE5-I.
      • Tapson V.F.
      • Torres F.
      • Kermeen F.
      • et al.
      Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trial.
      The neutral results were attributed to higher dose tablets causing poor tolerability. However, in the subsequent FREEDOM C2 study,
      • Tapson V.F.
      • Jing Z.C.
      • Xu K.F.
      • et al.
      Oral treprostinil for the treatment of pulmonary arterial hypertension in patients receiving background endothelin receptor antagonist and phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C2 study): a randomized controlled trial.
      despite using lower dose tablets, oral treprostinil showed no improvement in 6MWD at 16 weeks as an add-on therapy in patients who were on background therapy with an ERA or PDE5-I.

      Initial double combination therapy

      Data are emerging for initial combination therapy at the time of treatment initiation with drugs targeting more than one pathogenic pathway involved in PAH. In the BREATHE-2 trial, upfront combination therapy with bosentan and epoprostenol was not superior to epoprostenol monotherapy in improving functional capacity and hemodynamics at 12 weeks.
      • Humbert M.
      • Barst R.J.
      • Robbins I.M.
      • et al.
      Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2.
      However, the study was likely underpowered, with only 30 patients recruited.
      The AMBITION trial is the first strategic trial ever performed in PAH comparing initial combination therapy to monotherapy in newly diagnosed patients. It is an event-driven, multicenter, randomized, double-blind clinical trial that included 500 treatment-naive PAH patients with Functional Class II or III symptoms.
      • Galiè N.
      • Barberà J.A.
      • Frost A.E.
      • et al.
      Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension.
      Patients were randomized in a 2:1:1 fashion to a combination of ambrisentan and tadalafil, ambrisentan monotherapy or tadalafil monotherapy, respectively. The primary end-point was time to clinical failure, which is a composite of death, lung transplantation, hospitalization for PAH worsening, worsening PAH and persistent worsening after 6 months. Initial combination therapy with ambrisentan and tadalafil was associated with a 50% lower risk (HR = 0.50; 95% CI 0.35 to 0.72; p < 0.01) of primary end-point when compared with pooled results from the ambrisentan and tadalafil monotherapy groups. The combination therapy was also superior when compared with either monotherapy group individually. Of note, similar to other recent, event-driven, long-term clinical trials in PAH (SERAPHIN and GRIPHON), the difference in the primary end-point was driven mainly by the delay in time to first hospitalization and there was no difference in mortality between the treatment arms.
      • Humbert M.
      • Sitbon O.
      • Yaici A.
      • et al.
      Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension.
      More importantly, initial combination therapy was not associated with an increase in adverse events.

      Initial triple combination therapy

      The French network of PAH investigators reported their initial experience with upfront triple combination therapy targeting all 3 pathways implicated in the pathogenesis of PAH. They retrospectively reviewed 19 patients with severe hemodynamic compromise (cardiac index <2 liters/min/m2 and PVR >20 Wood units) who were initiated on bosentan, sildenafil and intravenous epoprostenol therapy simultaneously at the time of initial treatment.
      • Sitbon O.
      • Jais X.
      • Savale L.
      • et al.
      Upfront triple combination therapy in pulmonary arterial hypertension: a pilot study.
      Of the 19 patients, 18 had a significant improvement in 6MWD (463 ± 94 vs 227 ± 171 meters) and hemodynamics (cardiac index: 3.5 ± 0.7 vs 1.7 ± 0.4 liters/min/m2; PVR: 7.1 ± 3.3 vs 21.5 ± 7.8 Wood units) at 4 months compared with baseline, and these beneficial effects were sustained to final follow-up evaluation at 32 ± 10 months. One patient underwent heart–lung transplantation at 3 months. More importantly, the 1-, 2- and 3-year survival rates were 100%, significantly higher than that predicted by the French equation.
      • Humbert M.
      • Sitbon O.
      • Yaici A.
      • et al.
      Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension.
      Although these results are encouraging, the findings from this single-center, retrospective analysis and need further validation in well-designed, prospective clinical trials before widespread application can be recommended.

      Novel pathways and potential therapies in PAH

      In addition to the traditional pathways in PAH, emerging pre-clinical data suggest several additional pathways being involved in the pathogenesis of PAH, presenting potential new therapies for treatment (Table 2).
      • Galiè N.
      • Barberà J.A.
      • Frost A.E.
      • et al.
      Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension.
      • Humbert M.
      • Sitbon O.
      • Yaici A.
      • et al.
      Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension.
      • Sitbon O.
      • Jais X.
      • Savale L.
      • et al.
      Upfront triple combination therapy in pulmonary arterial hypertension: a pilot study.
      • Khush K.K.
      • Tasissa G.
      • Butler J.
      • et al.
      Effect of pulmonary hypertension on clinical outcomes in advanced heart failure: analysis of the Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness (ESCAPE) database.
      • Fang J.C.
      • DeMarco T.
      • Givertz M.M.
      • et al.
      World Health Organization Pulmonary Hypertension Group 2: Pulmonary hypertension due to left heart disease in the adult—a summary statement from the Pulmonary Hypertension Council of the International Society for Heart and Lung Transplantation.
      • Califf R.M.
      • Adams K.A.
      • McKenna W.J.
      • et al.
      A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: the Flolan International Randomized Survival Trial (FIRST).
      • Guazzi M.
      • Vicenzi M.
      • Arena R.
      • et al.
      Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study.
      • Guazzi M.
      • Vicenzi M.
      • Arena R.
      • et al.
      PDE5 inhibition with sildenafil improves left ventricular diastolic function, cardiac geometry, and clinical status in patients with stable systolic heart failure: results of a 1-year, prospective, randomized, placebo-controlled study.
      • Lewis G.D.
      • Shah R.
      • Shahzad K.
      • et al.
      Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension.
      • Lewis G.D.
      • Lachmann J.
      • Camuso J.
      • et al.
      Sildenafil improves exercise hemodynamics and oxygen uptake in patients with systolic heart failure.
      • Guazzi M.
      • Samaja M.
      • Arena R.
      • et al.
      Long-term use of sildenafil in the therapeutic management of heart failure.
      • Hoendermis E.S.
      • Liu L.C.
      • Hummel Y.M.
      • et al.
      Effects of sildenafil on invasive haemodynamics and exercise capacity in heart failure patients with preserved ejection fraction and pulmonary hypertension: a randomized controlled trial.
      • Anand I.
      • McMurray J.
      • Cohn J.N.
      • et al.
      Long-term effects of qdarusentan on left-ventricular remodelling and clinical outcomes in the EndothelinA Receptor Antagonist Trial in Heart Failure (EARTH): randomised, double-blind, placebo-controlled trial.
      • Kaluski E.
      • Kobrin I.
      • Zimlichman R.
      • et al.
      RITZ-5: randomized intravenous TeZosentan (an endothelin-A/B antagonist) for the treatment of pulmonary edema: a prospective, multicenter, double-blind, placebo-controlled study.
      • Kalra P.R.
      • Moon J.C.
      • Coats A.J.
      Do results of the ENABLE (Endothelin Antagonist Bosentan for Lowering Cardiac Events in Heart Failure) study spell the end for non-selective endothelin antagonism in heart failure?.
      • McMurray J.J.
      • Teerlink J.R.
      • Cotter G.
      • et al.
      Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials.
      • Bonderman D.
      • Ghio S.
      • Felix S.B.
      • et al.
      Riociguat for patients with pulmonary hypertension caused by systolic left ventricular dysfunction: a phase IIb double-blind, randomized, placebo-controlled, dose-ranging hemodynamic study.
      • Bonderman D.
      • Pretsch I.
      • Steringer-Mascherbauer R.
      • et al.
      Acute hemodynamic effects of riociguat in patients with pulmonary hypertension associated with diastolic heart failure (DILATE-1): a randomized, double-blind, placebo-controlled, single-dose study.
      • Seeger W.
      • Adir Y.
      • Barbera J.A.
      • et al.
      Pulmonary hypertension in chronic lung diseases.
      • Blanco I.
      • Ribas J.
      • Xaubet A.
      • et al.
      Effects of inhaled nitric oxide at rest and during exercise in idiopathic pulmonary fibrosis.
      • Voswinckel R.
      • Reichenberger F.
      • Enke B.
      • et al.
      Acute effects of the combination of sildenafil and inhaled treprostinil on haemodynamics and gas exchange in pulmonary hypertension.
      • King T.E.
      • Brown K.K.
      • Raghu G.
      • et al.
      BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis.
      • Raghu G.
      • Behr J.
      • Brown K.K.
      • et al.
      Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trial.
      • Raghu G.
      • Million-Rousseau R.
      • Morganti A.
      • et al.
      Macitentan for the treatment of idiopathic pulmonary fibrosis: the randomised controlled MUSIC trial.
      Idiopathic Pulmonary Fibrosis Clinical Research Network
      A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis.
      Of these various novel therapies, drugs targeting inflammation, growth factors, right ventricular metabolism and neurohormonal activation have made significant progress (currently in Phase II and III clinical trials) and appear promising for the near future.
      Table 2Novel Pathways and Potential Therapies for Pulmonary Arterial Hypertension
      PathwayPathogenic mechanismDrug
      Inflammation↑ IL-6, IL-1β, CX3CL1, abnormal T-cell, B-cell, NK cells, dendritic cellsCorticosteroids,
      • Furuya Y.
      • Satoh T.
      • Kuwana M.
      Interleukin-6 as a potential therapeutic target for pulmonary arterial hypertension.
      • Mizuno S.
      • Farkas L.
      • Al Husseini A.
      • et al.
      Severe pulmonary arterial hypertension induced by SU5416 and ovalbumin immunization.
      rituximab (anti-CD20 antibody),
      • Mizuno S.
      • Farkas L.
      • Al Husseini A.
      • et al.
      Severe pulmonary arterial hypertension induced by SU5416 and ovalbumin immunization.
      A Randomized, Double-Blind, Placebo-Controlled, Phase II Multicenter Trial of a Monoclonal Antibody to CD20 (Rituximab) for the Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH). Clinicaltrialsgov; NCT01086540.
      tocilizumab (anti-IL-6 antibody)
      • Arita Y.
      • Sakata Y.
      • Sudo T.
      • et al.
      The efficacy of tocilizumab in a patient with pulmonary arterial hypertension associated with Castleman׳s disease.
      BMPR-II/TGF-βLoss of function mutation of BMPR2, ALK1, endoglin, smad-9Tacrolimus,
      • Spiekerkoetter E.
      • Tian X.
      • Cai J.
      • et al.
      FK506 activates BMPR2, rescues endothelial dysfunction, and reverses pulmonary hypertension.
      ataluren
      • Drake K.M.
      • Dunmore B.J.
      • McNelly L.N.
      • Morrell N.W.
      • Aldred M.A.
      Correction of nonsense BMPR2 and SMAD9 mutations by ataluren in pulmonary arterial hypertension.
      Growth factorsPDGF, EGF, FGF, VEGF, C-kitTyrosine kinase inhibitors
      • Hoeper M.M.
      • Barst R.J.
      • Bourge R.C.
      • et al.
      Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMPRES study.
      Metabolic modulators↑ Glucose oxidation, ↑ fatty acid oxidationDichloroacetate,
      • Archer S.L.
      • Fang Y.H.
      • Ryan J.J.
      • Piao L.
      Metabolism and bioenergetics in the right ventricle and pulmonary vasculature in pulmonary hypertension.
      • Piao L.
      • Fang Y.H.
      • Cadete V.J.
      • et al.
      The inhibition of pyruvate dehydrogenase kinase improves impaired cardiac function and electrical remodeling in two models of right ventricular hypertrophy: resuscitating the hibernating right ventricle.
      ranolazine and triamterene
      • Fang Y.H.
      • Piao L.
      • Hong Z.
      • et al.
      Therapeutic inhibition of fatty acid oxidation in right ventricular hypertrophy: exploiting Randle׳s cycle.
      Neurohormonal activationSympathetic activation, renin-angiotensinogen-aldosterone activationβ-blockers (carvedilol, nevibilol and bisoprolol),
      • Perros F.
      • Ranchoux B.
      • Izikki M.
      • et al.
      Nebivolol for improving endothelial dysfunction, pulmonary vascular remodeling, and right heart function in pulmonary hypertension.
      • de Man F.S.
      • Handoko M.L.
      • van Ballegoij J.J.
      • et al.
      Bisoprolol delays progression towards right heart failure in experimental pulmonary hypertension.
      • Bogaard H.J.
      • Natarajan R.
      • Mizuno S.
      • et al.
      Adrenergic receptor blockade reverses right heart remodeling and dysfunction in pulmonary hypertensive rats.
      • Grinnan D.
      • Bogaard H.J.
      • Grizzard J.
      • et al.
      Treatment of group I pulmonary arterial hypertension with carvedilol is safe.
      ACE inhibitors/aldosterone antagonist
      • Maron B.A.
      • Waxman A.B.
      • Opotowsky A.R.
      • et al.
      Effectiveness of Spironolactone Plus Ambrisentan for Treatment of Pulmonary Arterial Hypertension (from the [ARIES] Study 1 and 2 Trials).
      • Maron B.A.
      • Zhang Y.Y.
      • White K.
      • et al.
      Aldosterone inactivates the endothelin-B receptor via a cysteinyl thiol redox switch to decrease pulmonary endothelial nitric oxide levels and modulate pulmonary arterial hypertension.
      • Maron B.A.
      • Leopold J.A.
      The role of the renin-angiotensin-aldosterone system in the pathobiology of pulmonary arterial hypertension (2013 Grover Conference series).
      Vasoactive mediatorsIncreased vasoconstriction due to ↑ 5HT, ↑TXA2, ↑ angiotensin II, ↓VIP, ↓ apelin5HT-receptor antagonists, SSRI,
      • Guignabert C.
      • Izikki M.
      • Tu L.I.
      • et al.
      Transgenic mice overexpressing the 5-hydroxytryptamine transporter gene in smooth muscle develop pulmonary hypertension.
      • Guignabert C.
      • Raffestin B.
      • Benferhat R.
      • et al.
      Serotonin transporter inhibition prevents and reverses monocrotaline-induced pulmonary hypertension in rats.
      inhaled nitrite,
      • Zuckerbraun B.S.
      • George P.
      • Gladwin M.T.
      Nitrite in pulmonary arterial hypertension: therapeutic avenues in the setting of dysregulated arginine/nitric oxide synthase signalling.
      adrenomedullin,
      • Harada-Shiba M.
      • Takamisawa I.
      • Miyata K.
      • et al.
      Intratracheal gene transfer of adrenomedullin using polyplex nanomicelles attenuates monocrotaline-induced pulmonary hypertension in rats.
      VIP,
      • Leuchte H.H.
      • Baezner C.
      • Baumgartner R.A.
      • et al.
      Inhalation of vasoactive intestinal peptide in pulmonary hypertension.
      apelin
      • Kim J.
      Apelin-APJ signaling: a potential therapeutic target for pulmonary arterial hypertension.
      Calcium signaling↓ SERCA2a, ↑ rho A/ROCKSERCA2a gene transfer,

      Hadri L, Kratlian RG, Benard L et al. Therapeutic Efficacy of AAV1.SERCA2a in Monocrotaline-Induced Pulmonary Arterial Hypertension. Circulation.

      rho kinase inhibition
      • Fukumoto Y.
      • Yamada N.
      • Matsubara H.
      • et al.
      Double-blind, placebo-controlled clinical trial with a rho-kinase inhibitor in pulmonary arterial hypertension.
      • Fukumoto Y.
      • Matoba T.
      • Ito A.
      • et al.
      Acute vasodilator effects of a Rho-kinase inhibitor, fasudil, in patients with severe pulmonary hypertension.
      ACE, angiotensin-converting enzyme; ALK, anaplastic lymphoma receptor tyrosine kinase; BMPR, bone morphogenetic protein receptor; EGF, epidermal growth factor; FGF, fibroblast growth factor; HT, hydroxytryptamine; IL, interleukin; NK, natural killer; PDGF, platelet-derived growth factor; TXA, thromboxane; VEGF, vascular endothelial growth factor; VIP, vasoactive intestinal peptide.

      Updates in other PH groups

      WHO Group 2: PH due to left heart disease (PH-LHD)

      PH-LHD is the most commonly encountered form of PH and is invariably linked to greater disability and decreased survival.
      • Khush K.K.
      • Tasissa G.
      • Butler J.
      • et al.
      Effect of pulmonary hypertension on clinical outcomes in advanced heart failure: analysis of the Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness (ESCAPE) database.
      Unfortunately, the pathophysiology of PH-LHD remains poorly understood, which results in a relative paucity of successful, targeted treatment strategies. Although small, single-center trials have shown improvements in exercise capacity and hemodynamic parameters, the results of randomized trials have been largely unsatisfactory. There are no Class I recommendations for targeted pulmonary vascular remodeling as treatment options for patients with PHLHD.
      • Fang J.C.
      • DeMarco T.
      • Givertz M.M.
      • et al.
      World Health Organization Pulmonary Hypertension Group 2: Pulmonary hypertension due to left heart disease in the adult—a summary statement from the Pulmonary Hypertension Council of the International Society for Heart and Lung Transplantation.
      In patients with elevated PVR, the role of PAH-approved therapies has been the subject of multiple, mostly unfavorable trials.
      • Califf R.M.
      • Adams K.A.
      • McKenna W.J.
      • et al.
      A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: the Flolan International Randomized Survival Trial (FIRST).
      PDE5-Is have the potential to decrease LV after-load and improve diastolic function, thereby improving PH hemodynamics and functional capacity in PH-LHD patients.
      • Guazzi M.
      • Vicenzi M.
      • Arena R.
      • et al.
      Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study.
      • Guazzi M.
      • Vicenzi M.
      • Arena R.
      • et al.
      PDE5 inhibition with sildenafil improves left ventricular diastolic function, cardiac geometry, and clinical status in patients with stable systolic heart failure: results of a 1-year, prospective, randomized, placebo-controlled study.
      • Lewis G.D.
      • Shah R.
      • Shahzad K.
      • et al.
      Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension.
      • Lewis G.D.
      • Lachmann J.
      • Camuso J.
      • et al.
      Sildenafil improves exercise hemodynamics and oxygen uptake in patients with systolic heart failure.
      • Guazzi M.
      • Samaja M.
      • Arena R.
      • et al.
      Long-term use of sildenafil in the therapeutic management of heart failure.
      However, treatment with sildenafil for 12 weeks did not reduce pulmonary artery pressure (PAP) and invasive hemodynamic or clinical parameters in 52 diastolic HF patients with predominantly isolated post-capillary PH.
      • Hoendermis E.S.
      • Liu L.C.
      • Hummel Y.M.
      • et al.
      Effects of sildenafil on invasive haemodynamics and exercise capacity in heart failure patients with preserved ejection fraction and pulmonary hypertension: a randomized controlled trial.
      A multicenter clinical trial evaluating sildenafil vs placebo in patients with PH due to systolic HF is currently enrolling patients (SilHF trial, NCT01616381).
      The hemodynamic alterations from earlier use of ERAs and prostanoids failed to translate into clinical benefit in multiple randomized, controlled trials.
      • Anand I.
      • McMurray J.
      • Cohn J.N.
      • et al.
      Long-term effects of qdarusentan on left-ventricular remodelling and clinical outcomes in the EndothelinA Receptor Antagonist Trial in Heart Failure (EARTH): randomised, double-blind, placebo-controlled trial.
      • Kaluski E.
      • Kobrin I.
      • Zimlichman R.
      • et al.
      RITZ-5: randomized intravenous TeZosentan (an endothelin-A/B antagonist) for the treatment of pulmonary edema: a prospective, multicenter, double-blind, placebo-controlled study.
      • Kalra P.R.
      • Moon J.C.
      • Coats A.J.
      Do results of the ENABLE (Endothelin Antagonist Bosentan for Lowering Cardiac Events in Heart Failure) study spell the end for non-selective endothelin antagonism in heart failure?.
      • McMurray J.J.
      • Teerlink J.R.
      • Cotter G.
      • et al.
      Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials.
      It should be noted that most of these studies did not stratify patients with LHD for the presence of PH or require optimization of volume status as criteria for inclusion. Therefore, they should not be totally eliminated as potential agents until they have been studied in appropriate clinical trials in PH-LHD. Recently, a trial with a non-selective ERA, bosentan, was completed in patients with diastolic HF and secondary PH (BADDHY trial, NCT00820352). A pilot Phase II study with macitentan (MELODY-1 trial, NCT02070991) has recently completed enrollment of patients with PH with HF and ejection fraction >35%.
      Riociguat, although well tolerated, did not show a change in mean PAP after 16 weeks of use in a multicenter, randomized, placebo-controlled trial in patients with PH related to systolic HF.
      • Bonderman D.
      • Ghio S.
      • Felix S.B.
      • et al.
      Riociguat for patients with pulmonary hypertension caused by systolic left ventricular dysfunction: a phase IIb double-blind, randomized, placebo-controlled, dose-ranging hemodynamic study.
      Similarly, it showed improved hemodynamic parameters with no significant effect on mean PAP in patients with PH related to diastolic HF.
      • Bonderman D.
      • Pretsch I.
      • Steringer-Mascherbauer R.
      • et al.
      Acute hemodynamic effects of riociguat in patients with pulmonary hypertension associated with diastolic heart failure (DILATE-1): a randomized, double-blind, placebo-controlled, single-dose study.
      The Phase IIb trial studying the safety and efficacy of another soluble guanylate cyclase inhibitor, vericiguat, in both systolic (SOCRATES–REDUCED trial, NCT01951625) and diastolic HF (SOCRATES–PRESERVED trial, NCT01951638) recently concluded patient enrollment.

      WHO Group 3: PH due to lung disease and/or hypoxia

      Management of patients with PH associated with lung disease, including chronic obstructive pulmonary disease (COPD), sleep-disordered breathing and idiopathic pulmonary fibrosis (IPF), focuses on treatment of the underlying lung disease as per guidelines.
      • Seeger W.
      • Adir Y.
      • Barbera J.A.
      • et al.
      Pulmonary hypertension in chronic lung diseases.
      However, none of the current management guidelines of lung diseases focus on the vascular component of the disease, except for long-term oxygen treatment. Systemic PAH-approved therapies have the potential of worsening gas exchange in patients with lung disease due to differential interference in hypoxia-mediated vasoconstriction. As a result, inhaled agents (iloprost, treprostinil or nitric oxide) may be advantageous.
      • Blanco I.
      • Ribas J.
      • Xaubet A.
      • et al.
      Effects of inhaled nitric oxide at rest and during exercise in idiopathic pulmonary fibrosis.
      • Voswinckel R.
      • Reichenberger F.
      • Enke B.
      • et al.
      Acute effects of the combination of sildenafil and inhaled treprostinil on haemodynamics and gas exchange in pulmonary hypertension.
      The non-selective ERA bosentan was well tolerated but failed to improve the end-point of time to clinical worsening in a Phase III trial in IPF patients.
      • King T.E.
      • Brown K.K.
      • Raghu G.
      • et al.
      BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis.
      Findings regarding its use in patients with IPF-associated PH in a Phase IV trial (B-PHIT trial, NCT00637065) are not yet available. However, the selective ERA, ambrisentan, is contraindicated in IPF, given its increased rate of disease progression and hospitalization, as shown in the ARTEMIS-IPF study.
      • Raghu G.
      • Behr J.
      • Brown K.K.
      • et al.
      Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trial.
      Negative trial results have also been reported with macitentan and sildenafil in IPF.
      • Raghu G.
      • Million-Rousseau R.
      • Morganti A.
      • et al.
      Macitentan for the treatment of idiopathic pulmonary fibrosis: the randomised controlled MUSIC trial.
      Idiopathic Pulmonary Fibrosis Clinical Research Network
      A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis.
      A recent case series demonstrated sustained hemodynamic improvements in patients with interstitial lung disease (ILD)–PH after treatment with PDE5-I (sildenafil or tadalafil) in 10 patients.
      • Zimmermann G.S.
      • von Wulffen W.
      • Huppmann P.
      • et al.
      Haemodynamic changes in pulmonary hypertension in patients with interstitial lung disease treated with PDE-5 inhibitors.
      Riociguat was well tolerated and showed efficacy in lowering PVR and increasing cardiac output and 6MWD in patients with diffuse parenchymal lung disease, but it failed to meet the primary end-point of reduction in PAP.
      • Hoeper M.M.
      • Halank M.
      • Wilkens H.
      • et al.
      Riociguat for interstitial lung disease and pulmonary hypertension: a pilot trial.
      In COPD, it is increasingly challenging to use directed vasodilator therapies given the risk of worsening gas exchange.
      • Wrobel J.P.
      • Thompson B.R.
      • Williams T.J.
      Mechanisms of pulmonary hypertension in chronic obstructive pulmonary disease: a pathophysiologic review.
      For example, use of bosentan in COPD patients with PH not only caused deterioration in gas exchange, but also failed to improve exercise capacity or quality of life in a small, randomized, controlled trial.
      • Stolz D.
      • Rasch H.
      • Linka A.
      • et al.
      A randomised, controlled trial of bosentan in severe COPD.
      There have been no long-term clinical trials on use of prostanoids in PH–COPD. Both sildenafil and tadalafil have been reported to improve hemodynamics, but they have failed to improve exercise tolerance or quality of life in COPD patients with moderate to severe PH.
      • Blanco I.
      • Santos S.
      • Gea J.
      • et al.
      Sildenafil to improve respiratory rehabilitation outcomes in COPD: a controlled trial.
      • Goudie A.R.
      • Lipworth B.J.
      • Hopkinson P.J.
      • et al.
      Tadalafil in patients with chronic obstructive pulmonary disease: a randomised, double-blind, parallel-group, placebo-controlled trial.

      WHO Group 4: Chronic thromboembolic pulmonary hypertension (CTEPH)

      CTEPH is considered potentially curable with pulmonary thromboendarterectomy (PTE) surgery, which can be performed in select patients with low peri-operative mortality at experienced centers. However, not all CTEPH patients are considered operable and up to one third have persistent or recurrent CTEPH after the procedure.
      • Pepke-Zaba J.
      • Jansa P.
      • Kim N.H.
      • et al.
      Chronic thromboembolic pulmonary hypertension: role of medical therapy.
      • Kim N.H.
      • Delcroix M.
      • Jenkins D.P.
      • et al.
      Chronic thromboembolic pulmonary hypertension.
      There has been increasing focus on use of PAH-specific therapies in CTEPH patients, especially those considered inoperable with persistent PH post-operatively.
      • Cabrol S.
      • Souza R.
      • Jais X.
      • et al.
      Intravenous epoprostenol in inoperable chronic thromboembolic pulmonary hypertension.
      • Jenkins D.P.
      • Madani M.
      • Mayer E.
      • et al.
      Surgical treatment of chronic thromboembolic pulmonary hypertension.
      • Olschewski H.
      • Simonneau G.
      • Galie N.
      • et al.
      Inhaled iloprost for severe pulmonary hypertension.
      • Ghofrani H.A.
      • Schermuly R.T.
      • Rose F.
      • et al.
      Sildenafil for long-term treatment of nonoperable chronic thromboembolic pulmonary hypertension.
      • Reichenberger F.
      • Voswinckel R.
      • Enke B.
      • et al.
      Long-term treatment with sildenafil in chronic thromboembolic pulmonary hypertension.
      • Hoeper M.M.
      • Kramm T.
      • Wilkens H.
      • et al.
      Bosentan therapy for inoperable chronic thromboembolic pulmonary hypertension.
      • Hughes R.
      • George P.
      • Parameshwar J.
      • et al.
      Bosentan in inoperable chronic thromboembolic pulmonary hypertension.
      • Bonderman D.
      • Nowotny R.
      • Skoro-Sajer N.
      • et al.
      Bosentan therapy for inoperable chronic thromboembolic pulmonary hypertension.
      • Seyfarth H.J.
      • Hammerschmidt S.
      • Pankau H.
      • et al.
      Long-term bosentan in chronic thromboembolic pulmonary hypertension.
      • Jais X.
      • D׳Armini A.M.
      • Jansa P.
      • et al.
      Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension: BENEFiT (Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension), a randomized, placebo-controlled trial.
      • Ghofrani H.A.
      • Hoeper M.M.
      • Halank M.
      • et al.
      Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: a phase II study.
      • Ghofrani H.A.
      • D׳Armini A.M.
      • Grimminger F.
      • et al.
      Riociguat for the treatment of chronic thromboembolic pulmonary hypertension.
      A retrospective analysis of CTEPH patients referred for PTE at the University of California, San Diego from 2005 to 2007 addressed hemodynamic and clinical outcomes for patients undergoing PTE on PAH-specific therapy (bosentan, sildenafil or epoprostenol and combination therapy; n = 111) in a comparison with therapy-naive patients (n = 244). There was minimal benefit of treatment with PHT on pre-PTE mean PAP, but its use was associated with a significant delay in time to referral for PTE.
      • Jensen K.W.
      • Kerr K.M.
      • Fedullo P.F.
      • et al.
      Pulmonary hypertensive medical therapy in chronic thromboembolic pulmonary hypertension before pulmonary thromboendarterectomy.
      CHEST-1 randomized 261 patients with inoperable or persistent post-operative PH to riociguat vs placebo and showed improvement in 6MWD (46 meters from baseline; p < 0.0001), PVR (31% reduction in therapy; p < 0.001), NT-pro-BNP and New York Heart Association (NYHA) functional class.
      • Ghofrani H.A.
      • D׳Armini A.M.
      • Grimminger F.
      • et al.
      Riociguat for the treatment of chronic thromboembolic pulmonary hypertension.
      CHEST-2 was an open-label extension trial of the CHEST Phase III patients to investigate the long-term safety profile of riociguat.
      • Simonneau G.
      • D׳Armini A.M.
      • Ghofrani H.A.
      • et al.
      Riociguat for the treatment of chronic thromboembolic pulmonary hypertension: a long-term extension study (CHEST-2).
      The drug was well tolerated by the majority of patients. Compared with the baseline established by the CHEST-1 trial, after 1 year of CHEST-2, 6MWD improved by 54 ± 62 meters in the inoperable subgroup and 44 ± 64 m in the persistent/recurrent subgroup. Riociguat was approved for use in both PAH and CTEPH by the FDA in October 2013 and by the EMA in March 2014.
      A multicenter, randomized, double-blind, placebo-controlled trial is currently enrolling patients to study the safety and efficacy of macitentan (MERIT-1, NCT02021292) in patients with inoperable CTEPH.

      Balloon pulmonary angioplasty (BPA)

      Initially introduced in the 1980s, BPA as therapy for inoperable CTEPH has gained recent traction with single-center studies reporting hemodynamic improvement as well as improved safety and efficacy.
      • Sugimura K.
      • Fukumoto Y.
      • Satoh K.
      • et al.
      Percutaneous transluminal pulmonary angioplasty markedly improves pulmonary hemodynamics and long-term prognosis in patients with chronic thromboembolic pulmonary hypertension.
      • Kataoka M.
      • Inami T.
      • Hayashida K.
      • et al.
      Percutaneous transluminal pulmonary angioplasty for the treatment of chronic thromboembolic pulmonary hypertension.
      • Mizoguchi H.
      • Ogawa A.
      • Munemasa M.
      • et al.
      Refined balloon pulmonary angioplasty for inoperable patients with chronic thromboembolic pulmonary hypertension.
      • Andreassen A.K.
      • Ragnarsson A.
      • Gude E.
      • et al.
      Balloon pulmonary angioplasty in patients with inoperable chronic thromboembolic pulmonary hypertension.
      Although less invasive than PTE, BPA requires multiple procedures and has been associated with risks related to vascular access, intravenous contrast and cumulative radiation exposure. Patient selection for this procedure should occur in conjunction with consideration of approved medical therapy and in collaboration with established CTEPH centers.

      Conclusions

      PH is a complex, multidisciplinary disease, which continues to be associated with high morbidity and mortality. Recent advances have led to increased recognition of newer treatment pathways and better understanding of the pathophysiology of pulmonary vascular dynamics and their interplay with RV function. Although these strategies have resulted in delayed clinical worsening in PAH patients, their impact on reduction in mortality continues to be limited. This is in part due to the limited efficacy of available drugs and the fact that long-term trials used the time to first event as the primary end-points, although death is never the first event in PAH. Based on the emerging data, we believe that combination therapy (whether initial or sequential) is becoming the standard of care in treatment of PAH. Initial oral combination therapy will likely replace oral monotherapy in the management of low- to intermediate-risk PAH patients in the near future. Although oral drugs targeting the prostacyclin pathway are now available, they are limited in efficacy. Therefore, for high-risk patients, parenteral prostacyclin will likely remain the treatment of choice for now until more data become available. Results from ongoing investigational trials will likely continue to advance the field of available therapies in the future.

      Disclosure statement

      M.K.K. has received a speaker’s fee from Bayer Pharma. J.L.V. received consultancy and speaker’s fees from Actelion Pharmaceuticals and GlaxoSmithKline, and speaker’s fees from Bayer Pharma and travel grants from Bayer Pharma and United Therapeutics.
      The remaining authors have no conflicts of interest to disclose.

      References

        • McLaughlin V.V.
        • Archer S.L.
        • Badesch D.B.
        • et al.
        ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association.
        J Am Coll Cardiol. 2009; 53: 1573-1619
        • Simonneau G.
        • Gatzoulis M.A.
        • Adatia I.
        • et al.
        Updated clinical classification of pulmonary hypertension.
        J Am Coll Cardiol. 2013; 62: D34-D41
        • Galie N.
        • Corris P.A.
        • Frost A.
        • et al.
        Updated treatment algorithm of pulmonary arterial hypertension.
        J Am Coll Cardiol. 2013; 62: D60-D72
        • Farber H.W.
        • Loscalzo J.
        Pulmonary arterial hypertension.
        N Engl J Med. 2004; 351: 1655-1665
        • Thenappan T.
        • Shah S.J.
        • Rich S.
        • et al.
        Survival in pulmonary arterial hypertension: a reappraisal of the NIH risk stratification equation.
        Eur Respir J. 2010; 35: 1079-1087
        • Benza R.L.
        • Miller D.P.
        • Gomberg-Maitland M.
        • et al.
        Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL).
        Circulation. 2010; 122: 164-172
        • Galiè N.
        • Humbert M.
        • Vachiery J.L.
        • et al.
        2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: the Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS) Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT).
        Eur Heart J. 2016; 37: 67-119
        • Tuder R.M.
        • Archer S.L.
        • Dorfmuller P.
        • et al.
        Relevant issues in the pathology and pathobiology of pulmonary hypertension.
        J Am Coll Cardiol. 2013; 62: D4-12
        • Jing Z.C.
        • Parikh K.
        • Pulido T.
        • et al.
        Efficacy and safety of oral treprostinil monotherapy for the treatment of pulmonary arterial hypertension: a randomized, controlled trial.
        Circulation. 2013; 127: 624-633
        • Peterson L.
        • Marbury T.
        • Marier J.
        • et al.
        An evaluation of the pharmacokinetics of treprostinil diolamine in subjects with hepatic impairment.
        J Clin Pharm Ther. 2013; 38: 518-523
        • Morrison K.
        • Ernst R.
        • Hess P.
        • et al.
        Selexipag: a selective prostacyclin receptor agonist that does not affect rat gastric function.
        J Pharmacol Exp Ther. 2010; 335: 249-255
        • Simonneau G.
        • Torbicki A.
        • Hoeper M.M.
        • et al.
        Selexipag: an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension.
        Eur Respir J. 2012; 40: 874-880
        • Sitbon O
        • Channick R
        • Chin K
        • et al.
        Selexipag for the Treatment of Pulmonary Arterial Hypertension.
        N Engl J Med. 2015; 373: 2522-2533
        • Pulido T.
        • Adzerikho I.
        • Channick R.N.
        • et al.
        Macitentan and morbidity and mortality in pulmonary arterial hypertension.
        N Engl J Med. 2013; 369: 809-818
        • Archer S.L.
        Riociguat for pulmonary hypertension—a glass half full.
        N Engl J Med. 2013; 369: 386-388
        • Ghofrani H.A.
        • Galie N.
        • Grimminger F.
        • et al.
        Riociguat for the treatment of pulmonary arterial hypertension.
        N Engl J Med. 2013; 369: 330-340
        • Galie N.
        • Muller K.
        • Scalise A.V.
        • et al.
        PATENT PLUS: a blinded, randomised and extension study of riociguat plus sildenafil in pulmonary arterial hypertension.
        Eur Respir J. 2015; 45: 1314-1322
        • McLaughlin V.
        • Channick R.N.
        • Ghofrani H.A.
        • et al.
        Bosentan added to sildenafil therapy in patients with pulmonary arterial hypertension.
        Eur Respir J. 2015; 46: 405-413
        • Tapson V.F.
        • Torres F.
        • Kermeen F.
        • et al.
        Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trial.
        Chest. 2012; 142: 1383-1390
        • Tapson V.F.
        • Jing Z.C.
        • Xu K.F.
        • et al.
        Oral treprostinil for the treatment of pulmonary arterial hypertension in patients receiving background endothelin receptor antagonist and phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C2 study): a randomized controlled trial.
        Chest. 2013; 144: 952-958
        • Humbert M.
        • Barst R.J.
        • Robbins I.M.
        • et al.
        Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2.
        Eur Respir J. 2004; 24: 353-359
        • Galiè N.
        • Barberà J.A.
        • Frost A.E.
        • et al.
        Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension.
        N Engl J Med. 2015; 373: 834-844
        • Humbert M.
        • Sitbon O.
        • Yaici A.
        • et al.
        Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension.
        Eur Respir J. 2010; 36: 549-555
        • Sitbon O.
        • Jais X.
        • Savale L.
        • et al.
        Upfront triple combination therapy in pulmonary arterial hypertension: a pilot study.
        Eur Respir J. 2014; 43: 1691-1697
        • Khush K.K.
        • Tasissa G.
        • Butler J.
        • et al.
        Effect of pulmonary hypertension on clinical outcomes in advanced heart failure: analysis of the Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness (ESCAPE) database.
        Am Heart J. 2009; 157: 1026-1034
        • Fang J.C.
        • DeMarco T.
        • Givertz M.M.
        • et al.
        World Health Organization Pulmonary Hypertension Group 2: Pulmonary hypertension due to left heart disease in the adult—a summary statement from the Pulmonary Hypertension Council of the International Society for Heart and Lung Transplantation.
        J Heart Lung Transplant. 2012; 31: 913-933
        • Califf R.M.
        • Adams K.A.
        • McKenna W.J.
        • et al.
        A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: the Flolan International Randomized Survival Trial (FIRST).
        Am Heart J. 1997; 134: 44-54
        • Guazzi M.
        • Vicenzi M.
        • Arena R.
        • et al.
        Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study.
        Circulation. 2011; 124: 164-174
        • Guazzi M.
        • Vicenzi M.
        • Arena R.
        • et al.
        PDE5 inhibition with sildenafil improves left ventricular diastolic function, cardiac geometry, and clinical status in patients with stable systolic heart failure: results of a 1-year, prospective, randomized, placebo-controlled study.
        Circ Heart Fail. 2011; 4: 8-17
        • Lewis G.D.
        • Shah R.
        • Shahzad K.
        • et al.
        Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension.
        Circulation. 2007; 116: 1555-1562
        • Lewis G.D.
        • Lachmann J.
        • Camuso J.
        • et al.
        Sildenafil improves exercise hemodynamics and oxygen uptake in patients with systolic heart failure.
        Circulation. 2007; 115: 59-66
        • Guazzi M.
        • Samaja M.
        • Arena R.
        • et al.
        Long-term use of sildenafil in the therapeutic management of heart failure.
        J Am Coll Cardiol. 2007; 50: 2136-2144
        • Hoendermis E.S.
        • Liu L.C.
        • Hummel Y.M.
        • et al.
        Effects of sildenafil on invasive haemodynamics and exercise capacity in heart failure patients with preserved ejection fraction and pulmonary hypertension: a randomized controlled trial.
        Eur Heart J. 2015; 36: 2565-2573
        • Anand I.
        • McMurray J.
        • Cohn J.N.
        • et al.
        Long-term effects of qdarusentan on left-ventricular remodelling and clinical outcomes in the EndothelinA Receptor Antagonist Trial in Heart Failure (EARTH): randomised, double-blind, placebo-controlled trial.
        Lancet. 2004; 364: 347-354
        • Kaluski E.
        • Kobrin I.
        • Zimlichman R.
        • et al.
        RITZ-5: randomized intravenous TeZosentan (an endothelin-A/B antagonist) for the treatment of pulmonary edema: a prospective, multicenter, double-blind, placebo-controlled study.
        J Am Coll Cardiol. 2003; 41: 204-210
        • Kalra P.R.
        • Moon J.C.
        • Coats A.J.
        Do results of the ENABLE (Endothelin Antagonist Bosentan for Lowering Cardiac Events in Heart Failure) study spell the end for non-selective endothelin antagonism in heart failure?.
        Int J Cardiol. 2002; 85: 195-197
        • McMurray J.J.
        • Teerlink J.R.
        • Cotter G.
        • et al.
        Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials.
        JAMA. 2007; 298: 2009-2019
        • Bonderman D.
        • Ghio S.
        • Felix S.B.
        • et al.
        Riociguat for patients with pulmonary hypertension caused by systolic left ventricular dysfunction: a phase IIb double-blind, randomized, placebo-controlled, dose-ranging hemodynamic study.
        Circulation. 2013; 128: 502-511
        • Bonderman D.
        • Pretsch I.
        • Steringer-Mascherbauer R.
        • et al.
        Acute hemodynamic effects of riociguat in patients with pulmonary hypertension associated with diastolic heart failure (DILATE-1): a randomized, double-blind, placebo-controlled, single-dose study.
        Chest. 2014; 146: 1274-1285
        • Seeger W.
        • Adir Y.
        • Barbera J.A.
        • et al.
        Pulmonary hypertension in chronic lung diseases.
        J Am Coll Cardiol. 2013; 62: D109-D116
        • Blanco I.
        • Ribas J.
        • Xaubet A.
        • et al.
        Effects of inhaled nitric oxide at rest and during exercise in idiopathic pulmonary fibrosis.
        J Appl Physiol (1985). 2011; 110: 638-645
        • Voswinckel R.
        • Reichenberger F.
        • Enke B.
        • et al.
        Acute effects of the combination of sildenafil and inhaled treprostinil on haemodynamics and gas exchange in pulmonary hypertension.
        Pulmon Pharmacol Ther. 2008; 21: 824-832
        • King T.E.
        • Brown K.K.
        • Raghu G.
        • et al.
        BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis.
        Am J Respir Crit Care Med. 2011; 184: 92-99
        • Raghu G.
        • Behr J.
        • Brown K.K.
        • et al.
        Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trial.
        Ann Intern Med. 2013; 158: 641-649
        • Raghu G.
        • Million-Rousseau R.
        • Morganti A.
        • et al.
        Macitentan for the treatment of idiopathic pulmonary fibrosis: the randomised controlled MUSIC trial.
        Eur Respir J. 2013; 42: 1622-1632
        • Idiopathic Pulmonary Fibrosis Clinical Research Network
        A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis.
        N Engl J Med. 2010; 363: 620-628
        • Zimmermann G.S.
        • von Wulffen W.
        • Huppmann P.
        • et al.
        Haemodynamic changes in pulmonary hypertension in patients with interstitial lung disease treated with PDE-5 inhibitors.
        Respirology. 2014; 19: 700-706
        • Hoeper M.M.
        • Halank M.
        • Wilkens H.
        • et al.
        Riociguat for interstitial lung disease and pulmonary hypertension: a pilot trial.
        Eur Respir J. 2013; 41: 853-860
        • Wrobel J.P.
        • Thompson B.R.
        • Williams T.J.
        Mechanisms of pulmonary hypertension in chronic obstructive pulmonary disease: a pathophysiologic review.
        J Heart Lung Transplant. 2012; 31: 557-564
        • Stolz D.
        • Rasch H.
        • Linka A.
        • et al.
        A randomised, controlled trial of bosentan in severe COPD.
        Eur Respir J. 2008; 32: 619-628
        • Blanco I.
        • Santos S.
        • Gea J.
        • et al.
        Sildenafil to improve respiratory rehabilitation outcomes in COPD: a controlled trial.
        Eur Respir J. 2013; 42: 982-992
        • Goudie A.R.
        • Lipworth B.J.
        • Hopkinson P.J.
        • et al.
        Tadalafil in patients with chronic obstructive pulmonary disease: a randomised, double-blind, parallel-group, placebo-controlled trial.
        Lancet Respir Med. 2014; 2: 293-300
        • Pepke-Zaba J.
        • Jansa P.
        • Kim N.H.
        • et al.
        Chronic thromboembolic pulmonary hypertension: role of medical therapy.
        Eur Respir J. 2013; 41: 985-990
        • Kim N.H.
        • Delcroix M.
        • Jenkins D.P.
        • et al.
        Chronic thromboembolic pulmonary hypertension.
        J Am Coll Cardiol. 2013; 62: D92-D99
        • Cabrol S.
        • Souza R.
        • Jais X.
        • et al.
        Intravenous epoprostenol in inoperable chronic thromboembolic pulmonary hypertension.
        J Heart Lung Transplant. 2007; 26: 357-362
        • Jenkins D.P.
        • Madani M.
        • Mayer E.
        • et al.
        Surgical treatment of chronic thromboembolic pulmonary hypertension.
        Eur Respir J. 2013; 41: 735-742
        • Olschewski H.
        • Simonneau G.
        • Galie N.
        • et al.
        Inhaled iloprost for severe pulmonary hypertension.
        N Engl J Med. 2002; 347: 322-329
        • Ghofrani H.A.
        • Schermuly R.T.
        • Rose F.
        • et al.
        Sildenafil for long-term treatment of nonoperable chronic thromboembolic pulmonary hypertension.
        Am J Respir Crit Care Med. 2003; 167: 1139-1141
        • Reichenberger F.
        • Voswinckel R.
        • Enke B.
        • et al.
        Long-term treatment with sildenafil in chronic thromboembolic pulmonary hypertension.
        Eur Respir J. 2007; 30: 922-927
        • Hoeper M.M.
        • Kramm T.
        • Wilkens H.
        • et al.
        Bosentan therapy for inoperable chronic thromboembolic pulmonary hypertension.
        Chest. 2005; 128: 2363-2367
        • Hughes R.
        • George P.
        • Parameshwar J.
        • et al.
        Bosentan in inoperable chronic thromboembolic pulmonary hypertension.
        Thorax. 2005; 60: 707
        • Bonderman D.
        • Nowotny R.
        • Skoro-Sajer N.
        • et al.
        Bosentan therapy for inoperable chronic thromboembolic pulmonary hypertension.
        Chest. 2005; 128: 2599-2603
        • Seyfarth H.J.
        • Hammerschmidt S.
        • Pankau H.
        • et al.
        Long-term bosentan in chronic thromboembolic pulmonary hypertension.
        Respiration. 2007; 74: 287-292
        • Jais X.
        • D׳Armini A.M.
        • Jansa P.
        • et al.
        Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension: BENEFiT (Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension), a randomized, placebo-controlled trial.
        J Am Coll Cardiol. 2008; 52: 2127-2134
        • Ghofrani H.A.
        • Hoeper M.M.
        • Halank M.
        • et al.
        Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: a phase II study.
        Eur Respir J. 2010; 36: 792-799
        • Ghofrani H.A.
        • D׳Armini A.M.
        • Grimminger F.
        • et al.
        Riociguat for the treatment of chronic thromboembolic pulmonary hypertension.
        N Engl J Med. 2013; 369: 319-329
        • Jensen K.W.
        • Kerr K.M.
        • Fedullo P.F.
        • et al.
        Pulmonary hypertensive medical therapy in chronic thromboembolic pulmonary hypertension before pulmonary thromboendarterectomy.
        Circulation. 2009; 120: 1248-1254
        • Simonneau G.
        • D׳Armini A.M.
        • Ghofrani H.A.
        • et al.
        Riociguat for the treatment of chronic thromboembolic pulmonary hypertension: a long-term extension study (CHEST-2).
        Eur Respir J. 2015; 45: 1293-1302
        • Sugimura K.
        • Fukumoto Y.
        • Satoh K.
        • et al.
        Percutaneous transluminal pulmonary angioplasty markedly improves pulmonary hemodynamics and long-term prognosis in patients with chronic thromboembolic pulmonary hypertension.
        Circ J. 2012; 76: 485-488
        • Kataoka M.
        • Inami T.
        • Hayashida K.
        • et al.
        Percutaneous transluminal pulmonary angioplasty for the treatment of chronic thromboembolic pulmonary hypertension.
        Circ Cardiovasc Interv. 2012; 5: 756-762
        • Mizoguchi H.
        • Ogawa A.
        • Munemasa M.
        • et al.
        Refined balloon pulmonary angioplasty for inoperable patients with chronic thromboembolic pulmonary hypertension.
        Circ Cardiovasc Interv. 2012; 5: 748-755
        • Andreassen A.K.
        • Ragnarsson A.
        • Gude E.
        • et al.
        Balloon pulmonary angioplasty in patients with inoperable chronic thromboembolic pulmonary hypertension.
        Heart. 2013; 99: 1415-1420
        • Humbert M.
        • Lau E.M.
        • Montani D.
        • et al.
        Advances in therapeutic interventions for patients with pulmonary arterial hypertension.
        Circulation. 2014; 130: 2189-2208
        • Furuya Y.
        • Satoh T.
        • Kuwana M.
        Interleukin-6 as a potential therapeutic target for pulmonary arterial hypertension.
        International journal of rheumatology. 2010; 2010: 720305
        • Mizuno S.
        • Farkas L.
        • Al Husseini A.
        • et al.
        Severe pulmonary arterial hypertension induced by SU5416 and ovalbumin immunization.
        Am J Respir Cell Mol Biol. 2012; 47: 679-687
      1. A Randomized, Double-Blind, Placebo-Controlled, Phase II Multicenter Trial of a Monoclonal Antibody to CD20 (Rituximab) for the Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH). Clinicaltrialsgov; NCT01086540.
        • Arita Y.
        • Sakata Y.
        • Sudo T.
        • et al.
        The efficacy of tocilizumab in a patient with pulmonary arterial hypertension associated with Castleman׳s disease.
        Heart and vessels. 2010; 25: 444-447
        • Spiekerkoetter E.
        • Tian X.
        • Cai J.
        • et al.
        FK506 activates BMPR2, rescues endothelial dysfunction, and reverses pulmonary hypertension.
        The Journal of clinical investigation. 2013; 123: 3600-3613
        • Drake K.M.
        • Dunmore B.J.
        • McNelly L.N.
        • Morrell N.W.
        • Aldred M.A.
        Correction of nonsense BMPR2 and SMAD9 mutations by ataluren in pulmonary arterial hypertension.
        Am J Respir Cell Mol Biol. 2013; 49: 403-409
        • Hoeper M.M.
        • Barst R.J.
        • Bourge R.C.
        • et al.
        Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMPRES study.
        Circulation. 2013; 127: 1128-1138
        • Archer S.L.
        • Fang Y.H.
        • Ryan J.J.
        • Piao L.
        Metabolism and bioenergetics in the right ventricle and pulmonary vasculature in pulmonary hypertension.
        Pulmonary circulation. 2013; 3: 144-152
        • Piao L.
        • Fang Y.H.
        • Cadete V.J.
        • et al.
        The inhibition of pyruvate dehydrogenase kinase improves impaired cardiac function and electrical remodeling in two models of right ventricular hypertrophy: resuscitating the hibernating right ventricle.
        Journal of molecular medicine. 2010; 88: 47-60
        • Fang Y.H.
        • Piao L.
        • Hong Z.
        • et al.
        Therapeutic inhibition of fatty acid oxidation in right ventricular hypertrophy: exploiting Randle׳s cycle.
        Journal of molecular medicine. 2012; 90: 31-43
        • Perros F.
        • Ranchoux B.
        • Izikki M.
        • et al.
        Nebivolol for improving endothelial dysfunction, pulmonary vascular remodeling, and right heart function in pulmonary hypertension.
        J Am Coll Cardiol. 2015; 65: 668-680
        • de Man F.S.
        • Handoko M.L.
        • van Ballegoij J.J.
        • et al.
        Bisoprolol delays progression towards right heart failure in experimental pulmonary hypertension.
        Circ Heart Fail. 2012; 5: 97-105
        • Bogaard H.J.
        • Natarajan R.
        • Mizuno S.
        • et al.
        Adrenergic receptor blockade reverses right heart remodeling and dysfunction in pulmonary hypertensive rats.
        Am J Respir Crit Care Med. 2010; 182: 652-660
        • Grinnan D.
        • Bogaard H.J.
        • Grizzard J.
        • et al.
        Treatment of group I pulmonary arterial hypertension with carvedilol is safe.
        Am J Respir Crit Care Med. 2014; 189: 1562-1564
        • Maron B.A.
        • Waxman A.B.
        • Opotowsky A.R.
        • et al.
        Effectiveness of Spironolactone Plus Ambrisentan for Treatment of Pulmonary Arterial Hypertension (from the [ARIES] Study 1 and 2 Trials).
        Am J Cardiol. 2013;
        • Maron B.A.
        • Zhang Y.Y.
        • White K.
        • et al.
        Aldosterone inactivates the endothelin-B receptor via a cysteinyl thiol redox switch to decrease pulmonary endothelial nitric oxide levels and modulate pulmonary arterial hypertension.
        Circulation. 2012; 126: 963-974
        • Maron B.A.
        • Leopold J.A.
        The role of the renin-angiotensin-aldosterone system in the pathobiology of pulmonary arterial hypertension (2013 Grover Conference series).
        Pulmonary circulation. 2014; 4: 200-210
        • Guignabert C.
        • Izikki M.
        • Tu L.I.
        • et al.
        Transgenic mice overexpressing the 5-hydroxytryptamine transporter gene in smooth muscle develop pulmonary hypertension.
        Circulation research. 2006; 98: 1323-1330
        • Guignabert C.
        • Raffestin B.
        • Benferhat R.
        • et al.
        Serotonin transporter inhibition prevents and reverses monocrotaline-induced pulmonary hypertension in rats.
        Circulation. 2005; 111: 2812-2819
        • Zuckerbraun B.S.
        • George P.
        • Gladwin M.T.
        Nitrite in pulmonary arterial hypertension: therapeutic avenues in the setting of dysregulated arginine/nitric oxide synthase signalling.
        Cardiovascular research. 2011; 89: 542-552
        • Harada-Shiba M.
        • Takamisawa I.
        • Miyata K.
        • et al.
        Intratracheal gene transfer of adrenomedullin using polyplex nanomicelles attenuates monocrotaline-induced pulmonary hypertension in rats.
        Molecular therapy: the journal of the American Society of Gene Therapy. 2009; 17: 1180-1186
        • Leuchte H.H.
        • Baezner C.
        • Baumgartner R.A.
        • et al.
        Inhalation of vasoactive intestinal peptide in pulmonary hypertension.
        Eur Respir J. 2008; 32: 1289-1294
        • Kim J.
        Apelin-APJ signaling: a potential therapeutic target for pulmonary arterial hypertension.
        Molecules and cells. 2014; 37: 196-201
      2. Hadri L, Kratlian RG, Benard L et al. Therapeutic Efficacy of AAV1.SERCA2a in Monocrotaline-Induced Pulmonary Arterial Hypertension. Circulation.

        • Fukumoto Y.
        • Yamada N.
        • Matsubara H.
        • et al.
        Double-blind, placebo-controlled clinical trial with a rho-kinase inhibitor in pulmonary arterial hypertension.
        Circulation journal: official journal of the Japanese Circulation Society. 2013; 77: 2619-2625
        • Fukumoto Y.
        • Matoba T.
        • Ito A.
        • et al.
        Acute vasodilator effects of a Rho-kinase inhibitor, fasudil, in patients with severe pulmonary hypertension.
        Heart. 2005; 91: 391-392